[Form 4/A] Xtant Medical Holdings, Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Xtant Medical Holdings, Inc. director reports updated equity holdings through an amended Form 4. The filing shows the grant of 158,228 shares of common stock in the form of deferred stock units (DSUs) at a price of $0 on 11/15/2025 under the Amended and Restated 2023 Equity Incentive Plan. These DSUs will vest on November 15, 2026, if the individual continues to serve as a director through that date, and each DSU represents a contingent right to receive one share of common stock. Following this transaction, the reporting person beneficially owns 914,116 shares, which includes 465,570 shares issuable upon settlement of outstanding DSU awards, each subject to service-based vesting. The amendment states that its purpose is to correct the number of shares shown as beneficially held in the ownership column.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BAKEWELL JOHN K

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	158,228	$0.00	--

Holdings After Transaction: Common Stock — 914,116 shares (Direct)

Footnotes (1)

1. These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock. Includes 465,570 shares issuable upon settlement of DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates. The purpose of this Form 4 amendment is to correct the number of shares beneficially held in column 5.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

BAKEWELL JOHN K

(Last) (First) (Middle)

C/O XTANT MEDICAL HOLDINGS, INC.

664 CRUISER LANE

(Street)

BELGRADE MT 59714

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xtant Medical Holdings, Inc. [ XTNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/15/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/15/2025		A		158,228(1)	A	$0	914,116(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

2. Includes 465,570 shares issuable upon settlement of DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

3. The purpose of this Form 4 amendment is to correct the number of shares beneficially held in column 5.

	/s/ Amy Culbert, attorney-in-fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the XTNT director report on this amended Form 4?

The director reported an award of 158,228 deferred stock units (DSUs) in Xtant Medical Holdings, Inc. common stock granted on 11/15/2025 under the Amended and Restated 2023 Equity Incentive Plan.

When do the newly granted XTNT deferred stock units vest?

The 158,228 DSUs will vest on November 15, 2026, conditioned on the reporting person continuing to serve as a director of Xtant Medical Holdings, Inc. through that vesting date.

How many XTNT shares does the reporting person beneficially own after the transaction?

After the reported transaction, the individual beneficially owns 914,116 shares of Xtant Medical Holdings, Inc. common stock, including shares issuable upon settlement of DSU awards.

How many XTNT shares are tied to outstanding deferred stock unit awards?

The filing states that the beneficial ownership figure includes 465,570 shares issuable upon settlement of DSU awards granted under the Amended and Restated 2023 Equity Incentive Plan, subject to continued service-based vesting.

Why was this XTNT Form 4 filed as an amendment (Form 4/A)?

The amendment states its purpose is to correct the number of shares beneficially held that was previously reported in column 5 of the original Form 4.

What role does the reporting person hold at Xtant Medical Holdings, Inc.?

The form identifies the reporting person as a director of Xtant Medical Holdings, Inc., and the equity awards are conditioned on continuing in that director role through applicable vesting dates.